|
|
|
|
Keeping mAb aggregation under control is a persistent challenge in downstream processing. Explore how chromatography process development choices can significantly influence aggregate removal, and how a more deliberate approach can help deliver higher purity and yield.
|
|
|
|
|
Final UF/DF is a key risk point for mAb aggregation. Our new article highlights key process, formulation, and system design considerations to help keep aggregation low during final UF/DF.
|
|
|
|
|
Explore key mechanisms driving mAb aggregation and practical strategies to control aggregates during chromatography and ultrafiltration/diafiltration (UF/DF) process development.
|
|
|
|
|
Protect your most sensitive antibodies, like bsAbs and IgG4, from harsh low‑pH conditions with mild‑elution purification to preserve stability while boosting yield and quality in the capture step.
|
|
|
|
|
In this study, we’ll show you purification results of the single variable domain of heavy chain antibodies from camelid (VHH) and human fragmented antibody (Fab), demonstrating high binding capacities and yields for these targets in the capture step.
|
|
|
|
|
Learn scalable chromatography purification strategies, use advanced tools like SPR and SEC‑MALS to understand interactions and impurities, and see how integrated expertise and knowledge transfer speed development and strengthen long‑term process capability.
|
|
|
|
|
|
Increase Cell Culture Yield Without Increasing Aggregation
|
The HyClone™ Glycan supplement supports controlled galactosylation in CHO cells while maintaining overall culture performance, with minimal impact on key product quality attributes such as aggregates. By preserving product integrity during cell culture, it helps increase usable yield and provides a stronger foundation for downstream success.
|
|
• Request Information
|
|
|
|
|
|
|
|
|
|
|
|
